Paolo Tarantino: New Article on HER2DX Genomic Test in HER2-Positive Metastatic Breast Cancer - OncoDaily Paolo Tarantino: New Article on HER2DX Genomic Test in HER2-Positive Metastatic Breast Cancer / Aleix Prat, Aleksandra Lesniak, Angela Aguirre, Barbara Adamo,

New Article on HER2DX Genomic Test in HER2-Positive Metastatic Breast Cancer - Paolo Tarantino (@ptarantinomd.bsky.social)

oncodaily.com/voices/paolo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #HER2DX

Paolo Tarantino: Interesting data with HER2DX for predicting the benefit of 1L chemo-HP in HER2+ MBC - OncoDaily Paolo Tarantino: Interesting data with HER2DX for predicting the benefit of 1L chemo-HP in HER2+ MBC / cancer, health, medicine, OncoDaily, Oncology, Rodrigo

Interesting data with HER2DX for predicting the benefit of 1L chemo-HP in HER2+ MBC - Paolo Tarantino
@ptarantinomd.bsky.social

oncodaily.com/science/paol...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #HER2DX #MBC #BreastCancer

Feliç Dia de Sant Jordi!
#SantJordi2025
#HER2DX
#precisiononcology
#innovation

Reveal Genomics revoluciona l’oncologia amb un test genètic per personalitzar els tractaments La spin-off de l’Hospital Clínic de Barcelona fa tests diagnòstics per oncologia que utilitzen intel·ligència artificial

Moltes gràcies a @viaempresa.cat i a #AnaMariaGonzálezFranco per aquest article en què la nostra cofundadora i CEO #PatriciaVillagrasa parla dels inicis de la companyia amb el suport de @barcelonactiva.bsky.social , del nostre test #HER2DX, així com del futur que ens espera.
ow.ly/gX7V50VpGWb

On another great day for #HER2DX at St. Gallen Breast Cancer Conference, Dr. #MafaldaOliveira from #SOLTI discusses the DEFINITIVE trial, the first prospective #HER2DX trial across 44 hospitals in 7 countries.
#SGBCC2025
#breastcancer
#precisiononcology